A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
for B-cell Malignancies
10 locations incl. La Jolla
Sponsor: AstraZeneca
Sex: All·Age: 18+
Code: NCT06542250·Phase 1, Phase 2·Recruiting